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Abstract
Background: Delirium is highly problematic in palliative care (PC). Preliminary data indicate a potential role for
melatonin to prevent delirium, but no randomized controlled trials (RCTs) are reported in PC.
Methods: Patients aged ≥18 years, with advanced cancer, admitted to an inpatient Palliative Care Unit (PCU),
having a Palliative Performance Scale rating ≥ 30%, and for whom consent was obtained, were included in the
study. Patients with delirium on admission were excluded. The main study objectives were to assess the feasibility
issues of conducting a double-blind RCT of exogenous melatonin to prevent delirium in PC: recruitment, retention,
procedural acceptability, appropriateness of outcome measures, and preliminary efficacy and safety data. Study
participants were randomized in a double-blind, parallel designed study to receive daily melatonin 3 mg or placebo
orally at 21:00 over 28 days or less if incident delirium, death, discharge or withdrawal occurred earlier. Delirium was
diagnosed using the Confusion Assessment Method. Efficacy endpoints in the melatonin and placebo groups were
compared using time-to-event analysis: days from study entry to onset of incident delirium.
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Results: Over 16 months, 60/616 (9.7%; 95% CI: 7.5–12.4%) screened subjects were enrolled. The respective
melatonin (n = 30) vs placebo (n = 30) outcomes were: incident delirium in 11/30 (36.7%; 95%CI: 19.9–56.1%) vs 10/
30 (33%; 95% CI: 17.3–52.8%); early discharge (6 vs 5); withdrawal (6 vs 3); death (0 vs 1); and 7 (23%) vs 11 (37%)
reached the 28-day end point. The 25th percentile time-to-event were 9 and 18 days (log rank, χ2 = 0.62, p = 0.43)
in melatonin and placebo groups, respectively. No serious trial medication-related adverse effects occurred and the
core study procedures were acceptable. Compared to those who remained delirium-free during their study
participation, those who developed delirium (n = 21) had poorer functional (p = 0.036) and cognitive performance
(p = 0.013), and in particular, poorer attentional capacity (p = 0.003) at study entry.
Conclusions: A larger double-blind RCT is feasible, but both subject accrual and withdrawal rates signal a need for
multisite collaboration. The apparent trend for shorter time to incident delirium in the melatonin group bodes for
careful monitoring in a larger trial.
Trial registration: Registered on July 21st 2014 with ClinicalTrials.gov: NCT02200172.
Keywords: Melatonin, Delirium, Advanced cancer, Feasibility study, Randomized controlled trial, Sleep, Pilot,
Prevention
Background
Delirium is a recognized complication of medical illness,
particularly in older patients, in whom it is associated
with increased mortality, hospitalization and healthcare
costs [1]. In inpatient palliative care settings, the preva-
lence of delirium has been reported in the 20–42% range
on admission and up to 88% in the last hours or days of
life [2]. Delirium is an acute neurocognitive disturbance
in which one’s awareness of the immediate environment
is decreased and disordered attentional capacity is a core
feature; other cognitive deficits and perceptual abnor-
malities may also occur [3]. As a consequence of these
features and associated hypo- or hyperactive psycho-
motor changes, normal communication is impeded. The
collective syndromal features of delirium invariably
generate distress for patients and their families [4]; for
healthcare practitioners, delirium presents a barrier in
symptom assessment and a clinical management chal-
lenge, particularly when psychomotor agitation occurs
[5–7]. This is especially true in the context of advanced
disease and end-of-life care, in which patients’ physical
and functional decline confers a high level of baseline
vulnerability towards delirium precipitants such as infec-
tion and adverse medication effects [6].
The clinical management approach towards an episode
of delirium in the palliative care context is to identify
and treat correctable precipitating factors, if consistent
with the patient’s desired goals of care; in situations
where the desired goals of care are solely focussed on
comfort, or where the delirium precipitants are refrac-
tory to treatment, therapeutic intervention must then
focus on symptomatic management of distressing symp-
toms such as perceptual disturbance or agitation [8].
Antipsychotics have been advocated in the first line
pharmacological management of distressing delirium
symptoms [9, 10]. However, evidence is emerging that
antipsychotics have no preventative role and a limited
therapeutic role for delirium in hospitalized adults [11–
13]; in a recent trial in palliative care patients, antipsy-
chotics were in fact associated with worsening of mild to
moderate delirium when compared to placebo [14]. The
recommended overall management approach is shifting
towards greater preventive efforts, especially with non-
pharmacological interventions and minimizing anti-
psychotic use where possible [15]. Multi-component
non-pharmacological interventions, including mainten-
ance of sleep hygiene have remarkable efficacy in pre-
venting delirium in older people, [16, 17] but similar
interventions together with deprescribing showed no
benefit in preventing delirium in a palliative care popula-
tion study [18]. Sleep-wake cycle disturbance is not a
core diagnostic criterion for diagnosis of delirium, but
its prevalence in cancer patients with delirium has been
reported in the 75–100% range [19, 20]. Although the
pathophysiology of delirium is complex and not fully
understood, melatonin dysregulation and associated
sleep-wake cycle disturbance is postulated as one of the
mechanisms in the pathogenesis of delirium [21].
Melatonin is a natural hormone that is secreted pre-
dominantly by the pineal gland, particularly in response
to darkness onset, coinciding with the initiation and
maintenance of sleep; it has a major role in both the
regulation and synchronization of the sleep-wake cycle
and circadian rhythms [22]. In addition to its chronobio-
tic role, melatonin has diverse and complex oncostatic
and immunomodulatory properties [23–25]. Further-
more, altered circadian melatonin levels, particularly a
reduction in peak endogenous production, have been re-
ported in relation to various cancers, [26–28] healthy
ageing and cognitive impairment [29, 30]. Disturbed cir-
cadian production of melatonin has also been reported
in postoperative patients and those with critical illness,
Lawlor et al. BMC Palliative Care          (2020) 19:163 Page 2 of 17
particularly sepsis [31–33]. Melatonin dysregulation has
thus been demonstrated in most of the clinical popula-
tions at highest risk of delirium, which is the main hypo-
thetical basis of exogenously administering melatonin to
prevent delirium.
Although there is growing interest in the role of mela-
tonin and melatonin receptor agonists in promoting
sleep and preventing delirium in critical care and other
high-risk populations, [34] heterogeneity among delir-
ium prevention studies with melatonin supplementation
precludes broad conclusive recommendations [35]. Al-
though two systematic reviews and meta-analyses failed
to show statistically significant benefit in delirium pre-
vention for melatonin or its agonist, ramelteon across
postoperative, intensive care and older medical popula-
tions, [36, 37] a sub-group analysis estimated that mela-
tonin administration decreased the incidence of delirium
by 75% in older (> 65 years) medical patients [36]. Mean-
while, delirium prevention studies with melatonin sup-
plementation have not been published to date in the
palliative care population, whose clinical characteristics
are likely to have a shared overlap with the older medical
population.
Given the rationale for a randomized controlled trial
(RCT) to evaluate the role of melatonin in preventing
delirium in the palliative care population, and prior to
conducting such a trial, hereafter referred to as the main
study, a preliminary study was conducted to examine its
feasibility. The primary objectives of this feasibility study
were to determine (1) estimates of participant recruit-
ment and retention, (2) the appropriateness of the main
study’s outcome measures, based on both the frequency
of protocol violation and ascertainment of preliminary
data on time to onset of first incident episode of delir-
ium, cumulative incidence of delirium, incident rate of
delirium and the severity of delirium and insomnia (3)
the acceptability of study procedures, including assess-
ment tools to patients, their families and palliative care
unit staff. The secondary objectives of this feasibility
study were to (a) assess the feasibility of data collection
regarding predisposing and precipitating risk factors for
delirium, (b) facilitate the initial implementation of
standard delirium prevention and management guide-
lines on the palliative care unit, and (c) assess the safety
of the study interventions, based on preliminary esti-
mates of adverse events.
Methods
The methods have been described in detail in a previous
protocol publication and will be summarized here [38].
Study setting, design and sample size
The feasibility study was conducted in a 31-bed in-
patient, university teaching palliative care unit (PCU) at
Élisabeth Bruyère Hospital, Ottawa, Canada. The study
was a double-blind, randomized, parallel arm, placebo-
controlled, single centre trial of once daily, orally admin-
istered melatonin to prevent delirium in patients with
advanced cancer. The proposed primary outcome of the
main study is time-to-event survival (survival in this
context refers not to life survival but to remaining
delirium-free, albeit at risk of delirium) analysis for first
incident episode of delirium. This means that partici-
pants who do not develop delirium by the end of the
study period would be censored in the analysis; similarly,
those participants who might leave the study without de-
veloping delirium before the designated study period
ends would contribute at-risk time to the time-to-event
survival analysis, but would be censored at the time of
their leaving the study.
For time-to-event survival analysis, we anticipated a
25% incidence of delirium in the placebo arm of the
main study. Accounting for censoring, we estimated a
sample size requirement of N = 410 to detect an effect
size (hazard ratio) of 0.5, given an alpha level of 0.05 and
power of 80% in the main study. Consistent with litera-
ture recommendations, [39] a sample size requirement
of 60 (30 in each arm) was estimated for the feasibility
study, which was 15% of the sample size (N = 410) of the
main study. Feasibility targets were not formally pre-
specified for this single site study in anticipation that the
main study would likely require multisite participation.
The feasibility study assessed the proposed primary
and secondary outcomes of the main study: time in days
from study enrollment to first inpatient episode of delir-
ium (event) for 50% (often referred to as median survival
time) of each study group in the at-risk population; cu-
mulative incidence of delirium within the study period
of 28 days; incidence rate of delirium per person-time,
also known as incidence rate density; severity of incident
delirium and perceived sleep satisfaction. The use of
person-time incidence and time-to-event survival out-
comes rather than cumulative incidence within a certain
time interval accounts for those situations where the ob-
servation time differs between participants, or the popu-
lation at risk varies with time.
Study eligibility
Inclusion criteria: age ≥ 18 years; documented diagnosis
of advanced cancer; admitted to the inpatient PCU; a
rating ≥ 30% on the Palliative Performance Scale (PPS)
[40]; cognitive capacity to give informed consent, as
assessed by the attending physician, or if cognitively im-
paired, access of the study team to a substitute decision
maker (SDM) to obtain informed written consent.
Exclusion criteria: delirium present on admission, based
on a positive CAM assessment; known psychotic disorder
other than dementia; inability to take medications
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sublingually or via gastrostomy tube; known allergy to
melatonin or placebo content; use of melatonin within the
2 weeks preceding admission; patients on warfarin or
other oral anticoagulants; on other investigational agents
or treatments or on immunosuppressant medication in
the context of autoimmune disease or post organ trans-
plantation; communication problems that could not be
accommodated in the course of study assessments, includ-
ing deafness, tracheostomy, aphasia, dysarthria or emo-
tional distress; severe visual impairment or designated
legally blind; and pregnancy or lactation.
Recruitment and randomization
Consecutive potential study participants were
approached within 72 h of admission and assessed by
their attending physician regarding study eligibility
criteria; those eligible were referred to either a trained
clinical research nurse (CRN) or trained clinical research
assistant (CRA) from the study team, who provided
information verbally and in writing, and obtained
informed written consent before study enrollment of all
participants.
Using the Ottawa Hospital Research Institute (OHRI)
Data Management Services (a web-based randomization
system), a central randomization master list, incorporat-
ing a 1:1 ratio for melatonin to placebo, was pre-
generated by an independent statistician and sent by
secure electronic communication to the hospital’s Dir-
ector of Pharmacy. The melatonin drug and identical
placebo were packaged, and numbered as per the master
list. This list was kept confidential and secure by OHRI
Data Management Services, the Director of Pharmacy
and the specific pharmacy technician who prepackaged
the study (melatonin or placebo) medication. The label
of the study medications only broadly identified the con-
tents as “Melatonin/ Placebo Study Drug”. Allocation of
study group (melatonin or placebo) was concealed: the
study investigators, research nurse and assistant, the
PCU pharmacist, nurses, physicians, dispensing pharma-
cist and technician, and study participants were blinded
to the exact study medication.
Study drug administration protocol and safety
monitoring
Enrolled subjects were randomised to receive melatonin
3 mg (immediate release) or an identical (size, shape and
taste) placebo at 21:00 (+/− 1 h) on study day 1 (D1) and
daily thereafter until D28 or earlier in the event of death,
discharge, study withdrawal or diagnosis of incident
delirium. The study drugs were supplied by Jamieson
Laboratories Ltd., Windsor, Ontario, Canada.
The National Cancer Institute’s Common Terminology
Criteria for Adverse Events (NCI-CTAE, v 4.03) format
was used for adverse event recording and reporting [41].
An independent Data and Safety Monitoring Board
(DSMB) was established for the study and received regu-
lar standardized reports from the study team.
Additional measures and data recording
Routine physician assessments on the day of PCU ad-
mission include the Confusion Assessment Method
(CAM), [42, 43] a validated tool to screen for and diag-
nose delirium, and the Short Orientation Memory
Concentration Test (SOMCT), [44] a validated tool to
assess cognition. Routine nursing assessments included
8-hly delirium screening on a daily basis with the Nurs-
ing Delirium Screening Scale (Nu-DESC), a validated ob-
servational tool (score range 0–10) that was completed
in relation to each 8-hour nursing shift [45]. A score ≥ 2
on the Nu-DESC prompted an attending physician
CAM rating within 24 h. Symptom intensity is routinely
rated using the revised Edmonton Symptom Assessment
System (ESAS-r) [46] and cancer pain is classified using
the Edmonton Classification System for Cancer Pain
(ECS-CP) [47].
Specific study assessments included the following: the
Insomnia Severity Index (ISI), [48] which was conducted
on D1 (Study Day 1), D14 ± 2 days and D28 ± 2 days; the
Memorial Delirium Assessment Scale (MDAS), [49]
which was rated on weekdays (with reference to the
preceding 24 h) by the CRN within 24 ± 8 h of incident
delirium diagnosis; and the Clinician Global Rating
(CGR) of delirium severity (mild, moderate or severe),
which was rated by the attending physician at the time
of incident delirium diagnosis.
The designated goals of care, based on consensual in-
put from patient and/or SDM, were recorded at admis-
sion and at the day of diagnosis of incident delirium.
Consistent with patient and family wishes, the desig-
nated goals of care help to determine the degree of in-
tensity applied to the investigation and treatment of an
episode of delirium. This approach is consistent with the
Canadian Guidelines on the Assessment and Treatment
of Delirium in Older Adults at the End of Life, [50]
which were adapted and introduced at the commence-
ment of this feasibility study. The goals of care categor-
ies were as follows: “R” for full resuscitation; “M+T” for
medical and transfer (indicating full medical investiga-
tion and treatment on the PCU with the option to trans-
fer out to tertiary acute care as necessary for additional
investigations or treatments); “M” for medical investiga-
tion and treatment without transfer out; and “C” for
comfort only care.
Data relating to baseline or predisposing factors (at
D1) and acute onset precipitating factors at the time of
incident delirium were collected by the CRN or CRA
using standard checklists (see Additional files 1 and 2,
Table S1 and Table S2 with checklists for baseline/
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predisposing factors and acute onset precipitating fac-
tors, respectively). Within 3 days of delirium diagnosis,
the CRN or CRA also interviewed the attending phys-
ician of those study patients who developed incident
delirium and systematically recorded a checklist of po-
tential precipitant risk factors (categorized as definite,
probable, possible, present but apparently not contribu-
tory, and either ruled out or not present or not relevant)
associated with the episode of incident delirium. Labora-
tory and other investigations were conducted as per rou-
tine practice on the PCU and consistent with the
designated goals of care. Laboratory abnormalities were
designated as such based on their being outside of the
local laboratory reference range in all cases. The total
opioid dose in morphine oral equivalent, the corticoster-
oid daily dose in prednisone oral equivalent, the diaze-
pam oral equivalent benzodiazepine daily dose and the
total anticholinergic drug scale (ADS) score at D1 were
calculated in accordance with standard tables and
references [51–53]. The Charlson Co-morbidity Index
was rated on D1 [54].
Data analysis
The data analysis for the feasibility study was largely de-
scriptive. Categorical data were summarized as propor-
tions or percentages with 95% confidence intervals (CIs),
unless otherwise stated; continuous data were summa-
rized as medians with interquartile (Q1-Q3) ranges, as
most were not normally distributed. As a preliminary re-
port, statistically significant differences between the
study groups were analyzed using the Pearson Chi
Square or Fisher’s Exact Tests for categorical variables
and the Mann-Whitney Test for continuous variables.
Similarly, preliminary data regarding the time to event
of the first episode of delirium in the two study groups
was compared using a Kaplan-Meier analysis. Statistical
analyses reported in this paper were conducted using
Stata 14.1 (StataCorp LP, College Station, TX, USA).
Ethical approval and oversight requirements
A no objection letter was obtained from the Therapeutic
Products Directorate of Health Canada to proceed with
the study, which was sponsored by Bruyère Research In-
stitute. The study received ethical approval from the
Ottawa Health Sciences Network and Bruyère Research
Ethics Boards. In addition to providing regular reports
to the DSMB, an independent study monitor, who con-
ducted a site visit and review of procedures at the times
of 20th, 40th and 60th subject recruitment, was also
appointed. The trial was registered on July 21st 2014
with ClinicalTrials.gov: NCT02200172. The study ad-
heres to CONSORT guidelines for randomized pilot and
feasibility trials [55].
Results
Recruitment, retention and demographic characteristics
of participants
Over the course of 16 months from December 2014 to
March 2016, 60/616 (9.7%; 7.5–12.4%) screened subjects
were enrolled, 30 to each study arm. The numbers of ex-
cluded and included study subjects, and those in each
arm with study end points reached prior to 28 days, due
to discontinuation of study drug or study withdrawal,
death or discharge are summarized Fig. 1.
Of the 556 excluded patients, 396 failed to meet the
study eligibility requirements, most commonly due to
delirium on admission in 124/396 (31%), low PPS rat-
ing (n = 67, 17%) and communication problems in
(n = 59, 15%). Seven (23.3%; 9.9–42.3%) of the mela-
tonin and 11 (36.7%; 19.9–56.1%) of the placebo study
groups, a total of 18 (30%; 18.9–43.2%) completed the
study to its designated full duration of 28 days without
developing incident delirium. Among the remaining 21
(35%; 23.1–48.4%) participants whose study participa-
tion ended before 28 days without incident delirium
being recorded, 1 from the placebo group died; 6 ver-
sus 3 were withdrawn and 6 versus 5 were discharged
in the melatonin and placebo groups, respectively. The
study exit for all of these participants was within the
first 21 days.
The demographic, oncologic and comorbidity charac-
teristics of the 60 study participants are summarized ac-
cording to the randomized study groups in Table 1. The
median age (interquartile range) of the entire study sam-
ple was 67 (60–75) years, with an almost identical distri-
bution across the two study groups. Twenty-seven (45%)
of the study sample were female, with a similar sex dis-
tribution across the two study groups. The most com-
mon cancer in the study sample was lung cancer,
comprising of 20 (33%) of all of the cancers. The distri-
bution of both primary cancer and metastatic sites was
similar across the two study groups. One third of the
study sample had metastatic brain disease and 10% had
leptomeningeal disease. Median PPS and CCI values
were 40 (30–50) and 10 (9–12), respectfully. Of the 60
study participants, 37 (61.7%) had their goals of care
designated as medical at admission, whereas at the time
of diagnosis of incident delirium, 8 (38%) and 12 (57.1%)
of 21 participants with delirium had their goals of care
designated as medical and comfort only, respectively.
There were no statistically significant differences be-
tween the two study groups in relation to any of the
baseline demographic, oncologic or comorbidity charac-
teristics, including cancer pain mechanism, presence of
incident pain or ESAS-r symptom intensity profiles.
ESAS-r scores were most often missing for anxiety and
drowsiness: 5 ratings were missing for each of these in
the placebo group.
Lawlor et al. BMC Palliative Care          (2020) 19:163 Page 5 of 17
Baseline neurocognitive assessment
The results of baseline neurocognitive status assessments
in both study groups are summarized in Table 2. Al-
though one third of participants had university or third
level education, the educational status of 26 (43.3%) was
unknown. Consent was obtained from a SDM for 9
(15%) study participants. The distribution of patients
with a documented diagnosis of dementia or cognitive
impairment without dementia was similar in both study
groups, as was the SOCMT score, which had a median
of 2 (0–6) for the entire study sample. The presence or
absence of a documented episode of delirium in the last
year preceding their admission to the palliative care unit
was unknown in 11 (18.3%) participants; 13 (21.7%) par-
ticipants had a documented previous episode in this
time period. There were no statistical differences
between study groups in relation to most neurocognitive
parameter assessments: documented episodes of
delirium; documented diagnoses of mood or anxiety
disorders; and neurocognitive symptom profiles, as ob-
tained through the admission history from the patient or
SDM. The neurocognitive symptom profiles included
sleep pattern disturbance, which was present in 10
(16.7%) participants, and the median ISI score was 9 (3–
13) for the entire study sample. There were also no dif-
ferences between the study groups regarding the number
of psychoactive medications prescribed or their doses.
The missing data in relation to baseline neurocognitive
parameters were highest for diazepam equivalent dose:
6/30 (20%) participants in the melatonin group had
missing information for this.
Preliminary data on the outcome measures chosen for
main study
The assessment measures recorded in relation to inci-
dent delirium in the two study groups are compared in
Table 3. Incident delirium occurred in 21 (35%; 23.1–
48.4%) of participants; of these 10 (33.3%; 17.3–52.8%)
Fig. 1 CONSORT Flow Diagram. PPS: Palliative Performance Scale; SDM: Substitute Decision Maker; IC: Informed Consent
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Table 1 Demographic, baseline oncologic and comorbidity characteristics in randomized study groups
Characteristic Study Group All patients P value
Placebo n = 30 (%) Melatonin n = 30 (%) Total
n = 60 (%)
Age, yrsa 67 (60–76) 67 (59–75) 67 (60–75) 0.531
Sex: female 13 (43.3) 14 (46.7) 27 (45.0) 0.795
Primary cancer
Lung 12 (40.0) 8 (26.7) 20 (33.3) 0.531
Gastrointestinal 7 (23.3) 9 (30.0) 16 (26.7)
Genitourinary 4 (13.3) 4 (13.3) 8 (13.3)
Breast 4 (13.3) 2 (6.7) 6 (10.0)
Hematologic 1 (3.3) 1 (3.3) 2 (3.3)
Head & Neck 1 (3.3) 0 (0.0) 1 (1.67)
Primary Brain 0 (0.0) 2 (6.7) 2 (3.3)
Other 1 (3.3) 4 (13.3) 5 (8.3)
Metastatic sites of cancer
Lung 8 (26.7) 12 (40.0) 20 (33.3) 0.273
Liver 12 (40.0) 14 (46.7) 26 (43.3) 0.602
Brain 12 (40.0) 8 (26.7) 20 (33.3) 0.273
Leptomeningeal 5 (16.7) 1 (3.3) 6 (10.0) 0.195
Bone 17 (56.7) 14 (46.7) 31 (51.7) 0.438
Palliative Performance Scale (PPS)a 40 (30–50) 40 (30–50) 40 (30–50) 0.613
Charlson Comorbidity Index (CCI)a 10 (9–11) 10 (9–13) 10 (9–12) 0.270
Baseline Goals of Care
Comfort only 6 (20.0) 7 (23.3) 13 (21.7) 0.750
Medical 19 (63.3) 18 (60.0) 37 (61.7)
Medical & Transfer 5 (16.7) 4 (13.3) 9 (15.0)
Full Resuscitation 0 (0.0) 1 (3.3) 1 (1.67)
ECS-CPb Pain mechanism
No pain syndrome 4 (13.3) 8 (26.7) 12 (20.0) 0.076
Nociceptive 18 (60.0) 9 (30.0) 27 (45.0)
Neuropathic 8 (26.7) 12 (40.0) 20 (33.3)
Unknown or missing 0 (0) 1 (3.3) 1 (1.67)
ECS-CPb Incident pain
Present 15 (50.0) 13 (43.3) 28 (46.7) 0.606
Absent 14 (46.7) 17 (56.7) 31 (51.7)
Unknown or missing 1 (3.3) 0 (0) 1 (1.67)
ESAS-r symptom intensity,c
Paina 3 (2–3) 2 (0–5) 2.5 (1–4) 0.786
Tirednessa 5 (3–6) 4.5 (2–6.5) 5 (3–6) 0.525
Drowsinessa 3 (1–6) 4.5 (2–6.5) 4 (1–6) 0.413
Nauseaa 0 (0–2) 0 (0–0.5) 0 (0–1) 0.486
Lack of appetitea 3.5 (0–7) 3.5 (0–7) 3.5 (0–7) 0.923
Short of breatha 2 (0–4) 0 (0–2) 1 (0–3) 0.072
Depressiona 1 (0–3) 0 (0–3) 0.5 (0–3) 0.584
Anxietya 1 (0–4) 2 (0–5) 2 (0–4) 0.787
Well beinga 4.5 (2–6) 3.5 (2–5.5) 4 (2–6) 0.644
Sleepa 4 (0–6) 3.5 (0–6) 4 (0–6) 0.847
aContinuous variables expressed as median (Q1-Q3)
bECS-CP: Edmonton Classification System for Cancer Pain
cESAS-r: Edmonton Symptom Assessment System Revised; number of missing ratings (placebo, melatonin) for each symptom: pain (4, 2); tired (4, 2); drowsiness (5, 2);
nausea (4, 2); lack of appetite (4, 2); short of breath (4, 2); depression (4, 2) anxiety (5, 2); well being (4, 2); sleep (7, 2)
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were in the placebo group and 11 (36.7%; 19.9–56.1%) in
the melatonin group. The incidence rate or incidence
density of delirium was 0.019 or 1.9 cases/100 person-
days in the placebo group and 0.027 or 2.7/100 person-
days in the melatonin group. This resulted in an
incidence rate ratio of 1.40 (95% CI: 0.595–3.27) for the
melatonin compared to the placebo group (p = 0.45). As
only the melatonin group had reached the 50th percent-
ile of the at-risk study population by the end of the study
period, the first quartile delirium-free survival was used
instead of the median survival for comparison of the
study groups. Thus, the time in days for the first quartile
of the at-risk study population to have an event
(delirium) was 9 and 18 days (log rank, χ2 = 0.62, p =
0.43) in the melatonin and placebo groups, respectively
(see Fig. 2).
In regard to the severity of incident delirium, there
were 9 participants with missing MDAS ratings for their
Table 2 Baseline neurocognitive status and psychoactive medication profiles of study groups
Characteristic Study Group All patients P value
Placebo
n = 30 (%)
Melatonin
n = 30 (%)
Total
n = 60 (%)
Highest educational level achieved
Elementary 0 (0.0) 2 (6.7) 2 (3.3) 0.369
Junior High School 2 (6.7) 1 (3.3) 3 (5.0)
High School 4 (13.3) 5 (16.7) 9 (15.0)
University / 3rd level 8 (26.7) 12 (40.0) 20 (33.3)
Unknown 16 (53.3) 10 (33.3) 26 (43.3)
Consent obtained
Patient 24 (80.0) 26 (86.7) 50 (83.3) 0.731
Substitute 6 (20.0) 4 (13.3) 9 (15.0)
Dementia diagnosis documenteda 2 (6.7) 2 (6.7) 4 (6.7) 1.000
Cognitive impairment without dementia
Documented present 2 (6.7) 2 (6.7) 4 (6.7) 0.748
Unknown 1 (3.3) 2 (6.7) 3 (5.0)
Short Orientation Memory Concentration Test Score (SOMCT)b 2 (0–5) 3 (0–7) 2 (0–6) 0.307
Previous delirium episode
Documented record of occurrence 7 (23.3) 6 (20.0) 13 (21.7) 0.521
Unknown 7 (23.3) 4 (13.3) 11 (18.3)
Mood disorder diagnosis documenteda 2 (6.7) 6 (20.0) 8 (13.3) 0.357
Anxiety disorder documenteda 3 (10.0) 3 (10.0) 6 (10.0) 0.891
Recent neurocognitive symptoms (per history from patient or substitute)c
Perceptual disturbance 3 (10.0) 3 (10.0) 6 (10.0) 0.665
Delusional disturbance 0 (0) 0 (0) 0 (0) 0.385
Attention problemsa 5 (16.7) 7 (23.3) 12 (20.0) 0.658
Sleep pattern disturbeda 8 (26.7) 2 (6.7) 10 (16.7) 0.080
Insomnia severity index (ISI) scoreb 11 (4–15) 7.5 (2–13) 9 (3–13) 0.199
Psychoactive medications at admission
Number prescribedb 3 (1–4) 2 (1–3) 2 (1–4) 0.125
Morphine equivalent daily dose (MEDD)bd 60 (6–90) 37.5 (4–240) 54 (4.5–132) 0.645
Diazepam equivalent daily dosebd 0 (0) 0 (0) 0 (0) 0.931
Prednisone equivalent daily dosebd 11 (0–40) 16.25 (0–45) 12.25 (0–40.0) 0.757
aMissing data in study groups (placebo, melatonin) for categorical variables: dementia diagnosis documented (0, 1); mood disorder diagnosis documented (1, 1);
anxiety disorder documented (2, 4); attention problems (4, 2); sleep disturbed (0, 1); missing data were counted as values in statistical analyses
bContinuous variables expressed as median (Q1-Q3); missing data in study groups (placebo, melatonin) for continuous variables: SOMCT score (2, 3); ISI score (1,
0); psychoactive medications (1, 3); diazepam equivalent (4, 6); prednisone equivalent (0, 2)
cSubsyndromal delirium features in the absence of a documented diagnosis of delirium
dOral equivalent in milligrams
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first 24 h of incident delirium; comparison of the six avail-
able MDAS ratings in each group revealed higher severity
in the melatonin versus placebo group: 18 (16–20) versus
13.5 (11–17), (p = 0.09). There were no missing CGRs of
delirium severity and rating categories (mild, moderate
and severe) were not statistically different in the study
groups. Similarly, there were no statistically significant
study group differences in the maximum Nu-DESC score
either during the day of incident delirium diagnosis or in
the 72-h period that included the day before the day of in-
cident delirium diagnosis, the day of incident delirium
diagnosis and the day following this.
In rating the severity of insomnia, there were 28 (53%)
of participants with missing D14 ISI ratings and 43
Table 3 Incident delirium assessment measures
Characteristic Study Groups All patients P value
Placebo n = 30 (%) Melatonin n = 30 (%) Total n = 60 (%)
Incident Delirium Diagnosis (IDD)
Cumulative 28-day incidence 10 (33.3) 11 (36.7) 21 (35.0) 0.787
Total person-days at risk 521 411 932
Incidence rate per person-day [95% Confidence interval] 0.019 [0.010–0.036] 0.027 [0.015–0.048] 0.023[0.015–0.036] 0.227
First quartile delirium-free survival time (days) 18 9 10 0.433
Severity measures at IDD
MDASa completed < 24 h of IDD 6 (60.0) 6 (54.5) 12 (57.1) 0.331
MDAS scoreb 13.5 (11–17) 18 (16–20) 16.5 (12–18) 0.090
Clinician Global Rating (CGR)
Mild 2/10 [20.0] 3/11 [27.3] 5/21 [23.8] 0.632
Moderate 6/10 [60.0] 8/11 [72.7] 14/21 [66.7]
Severe 2/10 [20.0] 0/11 [0] 2/21 [9.5]
Nu-DESC ratingsc
Total number of ratings available over 72 hd at IDDb 7 (6–9) 8 (6–9) 8 (6–9) 0.462
Maximum total Nu-DESC score over 72 hd at IDDb 4 (3–6) 3 (1–5) 3 (2–5) 0.191
Maximum total Nu-DESC score during day of IDDb 6 (4–7) 3 (3–5) 4 (3–6) 0.144
aMDAS Memorial Delirium Assessment Scale; in the placebo group, 4 MDAS ratings were missing, and in the melatonin group, 5 were missing
bMedian (Q1-Q3)
cNu-DESC: Nursing Delirium Screening Scale Eastern; score range 0–10 relating to 8-h nursing shift
d72-h period refers to calendar day prior to day of IDD, the day of IDD, and the calendar day following the day of IDD
Fig. 2 Kaplan-Meier plots of cumulative incidence of delirium in study groups
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(72%) with missing D28 ISI ratings. Apart from a re-
ported ISI baseline comparison, in which treatment
group differences were not statistically significant, no
further study group comparisons were made in view of
the extent of missing data.
There was one protocol violation in the placebo group:
two doses of the placebo medication were missed in one
participant. There were 31 protocol deviations in the
placebo group and 18 in the melatonin group, mostly re-
lating to documentation and timing of assessments.
Acceptability of study procedures
Field notes were made by the CRN and CRA regarding
the acceptability of core study procedures. Apart from
issues with assessment tools, the study procedures were
otherwise considered acceptable. Missing assessments
occurred most frequently in relation to the MDAS
ratings and ISI ratings. Missing MDAS ratings were
attributed to lack of weekend CRN/CRA assessor cover-
age in 3 participants and patient fatigue or distress in
the remainder. In the case of participants with missing
ISI ratings, many had either been discharged or become
delirious before their ISI assessments that were sched-
uled on D14 or D28, or were noted to be too fatigued to
complete the assessment.
Secondary objectives
Data collection regarding delirium risk factors
The distribution of potential baseline risk factors in the
21 study participants who developed incident delirium is
compared to that of the 39 participants who remained
delirium free during the duration of their study partici-
pation is summarized in Table 4. Statistically significant
differences were determined for 3 potential risk factors:
compared to those who did not develop delirium, the
participants who developed delirium had poorer func-
tional status, as reflected by median (Q1-Q3) PPS scores
of 40 (30–40) versus 40 (30–50), p = 0.036; higher
SOMCT scores (reflecting poorer cognitive performance
at baseline), 6 (2–10) versus 2 (0–4), p = 0.013; and a
higher frequency of baseline deficits in attentional cap-
acity, 8 (38.1%) versus 4 (10.3%), p = 0.003, respectively.
Although this study proposed to record C-reactive pro-
tein (CRP) levels as a marker of inflammation at base-
line, only 7 participants had a recorded level. The study
also proposed to assess the ADS score as a potential
baseline measure of participants’ anticholinergic activity
profile, a potential risk factor for delirium, but due to
interpretative difficulties this information was not
recorded for any of the participants.
Precipitant risk factors for incident delirium as identi-
fied through interview of the attending physicians, are
presented in summarized category format both in Fig. 3
and Additional file 3, Table S3. There were no cases of
medication or substance withdrawal, even in the
“present but apparently not contributory” precipitant
category. Infection, metabolic or endocrine abnormal-
ities, organ insufficiency and medication adverse effect
or toxicity ranked as the most frequent precipitants in
the definite or probable categories.
Implementation of delirium assessment and management
guidelines
The conduct of this feasibility study was used as an
opportunity to implement standard clinical practice
guidelines regarding delirium assessment and manage-
ment on our PCU. These guidelines were implemented
for all members of the inter-professional team in a
modular fashion, with a focus on delirium screening,
nonpharmacological interventions, and improving com-
munication and support for patients and their families.
Recommendations for antipsychotic prescribing were
derived from recently published RCT evidence.
Safety evaluation
Although the total number of participants with at least
one CTCAE Grade 3–5 serious adverse event was 17
(57%) in the placebo study group and 20 (67%) in the
melatonin study group, these were considered to be not
related (n = 15) or unlikely to be related (n = 2) in the
placebo group and not related (n = 17) or unlikely to be
related (n = 3) in the melatonin group.
Discussion
There is a general consensus that a pilot or feasibility
study is practically a prerequisite requirement prior to
proceeding with a larger study, especially in palliative
care settings, whose population are particularly vulner-
able [56, 57]. Although the literature distinction between
pilot and feasibility studies is somewhat unclear, [58, 59]
there is some consensus that pilot studies are a subset of
feasibility studies [60]. In meeting its primary and sec-
ondary objectives, the current study, although referred
to as a feasibility study, provides useful information from
both the pilot and feasibility perspectives prior to con-
ducting the main RCT.
Primary feasibility of study objectives
Recruitment and retention
The presence of delirium at inpatient admission in 31%
of those not meeting inclusion criteria was the most fre-
quent reason for study exclusion. Of the 616 screened
subjects, 160 (26%) either declined to give informed
consent or declined contact from the CRN/CRA.
Approximately 10% of all screened subjects (N = 616)
were recruited in this study and although there was no
specific, a priori defined recruitment rate target, the re-
cruitment at our single site required a lengthy period of
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Table 4 Baseline risk factors according to occurrence of incident delirium
Characteristic Study Group All patients P value
No Delirium
n = 39 (%)
Delirium
n = 21 (%)
Total
n = 60 (%)
Age, yrsa 67 (60–75) 68 (61–75) 67 (60–75) 0.687
Sex: female 20 (51.3) 7 (33.3) 27 (45.0) 0.183
Primary cancer
Lung 13 (33.3) 7 (33.3) 20 (33.3) 0.544
Gastrointestinal 9 (23.1) 7 (33.3) 16 (26.7)
Genitourinary 6 (15.4) 2 (9.5) 8 (13.3)
Breast 5 (12.8) 1 (4.8) 6 (10.0)
Primary Brain 1 (2.6) 1 (4.8) 2 (3.3)
Hematologic 0 (0) 2 (9.5) 2 (3.3)
Head & Neck 1 (2.6) 0 (0) 1 (1.7)
Other 4 (10.3) 1 (4.8) 5 (8.3)
Metastatic sites of cancer
Lungs 14 (35.9) 6 (28.6) 20 (33.3) 0.566
Liver 17 (43.6) 9 (42.9) 26 (43.3) 0.956
Brain 11 (28.2) 9 (42.9) 20 (33.3) 0.251
Leptomeninges 3 (7.7) 3 (14.3) 6 (10.0) 0.078
Bone 21 (53.9) 10 (47.6) 31 (51.7) 0.645
Charlson Comorbidity Index (CCI)a 10 (9–12) 10 (9–13) 10 (9–12) 0.919
Palliative Performance Scorea 40 (30–50) 40 (30–40) 40 (30–50) 0.036
Baseline Goals of Care
Comfort only 7 (17.9) 6 (28.6) 13 (21.7) 0.301
Medical 23 (59.0) 14 (66.7) 37 (61.7)
Medical & Transfer to Acute Care 8 (20.5) 1 (4.8) 9 (15.0)
Full Resuscitation 1 (2.6) 0 (0) 1 (1.7)
Highest educational level achieved
Elementary 1 (2.6) 1 (4.76) 2 (3.3) 0.959
Junior High School 2 (5.13) 1 (4.76) 3 (5.00)
High School 6 (15.4) 3 (14.3) 9 (15)
University / 3rd level 12 (30.8) 8 (38.1) 20 (33.3)
Unknown 18 (46.5) 8 (38.1) 26 (43.3)
Cognitive and psychiatric status at admission
Short Orientation Memory Concentration Test Score (SOMCT)a 2 (0–4) 6 (2–10) 2 (0–6) 0.013
Recent neurocognitive symptoms (per admission history and assessments)b
Perceptual disturbance 3 (7.7) 3 (14.3) 6 (10.0) 0.417
Delusional disturbance 0 (0) 0 (0) 0 (0)
Attention problemsc 4 (10.3) 8 (38.1) 12 (20.0) 0.003
Sleep pattern disturbedc 7 (18.0) 3 (14.3) 10 (16.7) 0.443
Insomnia severity index (ISI) scorea 10 (3–14) 5.5 (1–12.5) 9 (3–13) 0.336
Previous delirium episode
Documented occurrence 7 (18.0) 6 (28.6) 13 (21.7) 0.562
Unknown 7 (18.0) 4 (19.1) 11 (18.3)
Dementia diagnosisc 3 (7.7) 1 (4.8) 4 (6.7) 0.536
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Table 4 Baseline risk factors according to occurrence of incident delirium (Continued)
Characteristic Study Group All patients P value
No Delirium
n = 39 (%)
Delirium
n = 21 (%)
Total
n = 60 (%)
Cognitive deficits without dementia
Documented 2 (5.1) 3 (14.3) 5 (8.3) 0.601
Unknown 2 (5.1) 1 (4.8) 3 (5.0)
Mood disorder diagnosisc 7 (18.0) 1 (4.8) 8 (13.3) 0.268
Anxiety disorder diagnosisc 3 (7.7) 3 (14.3) 6 (10.0) 0.546
Metabolic abnormalities at admission
Hypoalbuminemia 23 (59.0) 16 (76.2) 39 (65.0) 0.258
Hyponatremia 4 (10.3) 4 (19.1) 8 (13.3) 0.433
Hypercalcemia 2 (5.1) 1 (4.8) 3 (5.0) 1.000
Low Hemoglobin (< 100 g/L) 9 (23.1) 8 (38.1) 17 (28.3) 0.243
Hypoxia requiring Oxygen therapy 7 (18.0) 5 (23.8) 12 (20.0) 0.737
Medications at admission
Number of medications prescribeda 12 (10–16) 10.5 (8–14) 12 (8–15) 0.187
Psychoactive medicationsa 2 (1–4) 2 (1–4) 2 (1–4) 0.641
Morphine equivalent daily dose (MEDD)a 30 (5–150) 60 (2.5–90) 54 (4.5–132) 0.944
Diazepam equivalent daily dosea 0 (0) 0 (0) 0 (0) 0.487
Prednisone equivalent daily dosea 12.25 (0–40) 13 (0–50) 12.5 (0–40) 0.868
aContinuous variables as median (Q1-Q3) unless otherwise reported; missing data in groups (delirium, no delirium) for some continuous variables: SOMCT score (3,
2); ISI score (0, 1); total number of medications prescribed (2, 1); psychoactive medications (2, 2); diazepam equivalent (4, 6); prednisone equivalent (1, 1)
bFeatures of subsyndromal delirium in the absence of a documented diagnosis of delirium
cCategorical variables for which there was missing data in groups (no delirium, delirium): highest educational level achieved (18, 8); dementia diagnosis
documented (0, 1); cognitive impairment without dementia (2, 1); mood disorder (2, 0); anxiety disorder (5, 1); attention problems (2, 4); sleep disturbed (0, 1);
missing data were counted as values in statistical analyses
Fig. 3 Categorized precipitants of delirium for 20 participants with incident delirium. †Data were not recorded in this category for
two participants
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approximately 16 months. From a recruitment perspec-
tive, these data indicate that a larger RCT would clearly
require multisite collaboration.
Although a change in the study inclusion criteria to in-
clude participants with non-cancer end-of-life conditions
might broaden the study target population and boost re-
cruitment, it might also introduce a high degree of
heterogeneity and add further challenges in terms of
analyses. Nonetheless, this warrants consideration. The
feasibility study recruited patients with advanced cancer
that required inpatient PCU admission. It should be ac-
knowledged that targeting patients earlier in their cancer
disease trajectory might enhance recruitment potential
for a community-based study (as opposed to an inpatient
PCU study), but the validity of screening for and diag-
nosing delirium as an outcome in a community-based
setting would also pose major challenges.
In terms of retention, 21 (35%) study participants con-
tributed at-risk time from a time-to-event analysis per-
spective and exited the study prior to 21 days without
developing delirium, thus requiring right censoring in
the analysis. Of those who developed incident delirium,
all but 2 did so by 21 days. These data suggest that we
could consider shortening the duration of the main
study to 21 days with minimal loss of data, which might
be an acceptable trade-off, as multisite collaboration
might be more attractive with a shorter study duration.
Preliminary data on outcome measures for the main study
Although the extent of missing assessment score data
was substantial, this related mainly to outcomes that are
designated as secondary outcome measures in the main
study. The minimal protocol violation or deviation en-
countered in relation to the main study’s designated pri-
mary outcome measure supports its choice as primary
outcome measure for the main study. Meanwhile, pre-
liminary data obtained from the study regarding efficacy
of study medications and sample size estimates warrant
careful evaluation.
The study was remarkably informative regarding the
time-to-event for the occurrence of incident delirium.
However, caution should be exercised in relation to any
hypothesis testing or interpreting efficacy differences be-
tween the study groups, as this study was not adequately
powered to do so. Nonetheless, the signal highlights the
importance of a DSMB and careful tracking of trends in
both arms in the main study.
The study provided helpful pilot data in relation to the
sample size requirement for the main study, originally
estimated at 410. Although the 35% cumulative inci-
dence of delirium in the study sample was higher than
our pre-study projection of 25%, we under-estimated the
need to censor cases in the time-to-event analysis: in-
stead of the projected 10% withdrawal rate, there were
21 (35%) study participants who contributed at-risk time
and required right censoring, albeit at varying times
within the first 21 days of the study. Furthermore, our
pre-study effect size change, reflected by a hazard ratio
of 0.5 (a 50% reduction in hazard) and based on a previ-
ous study in a medical geriatric population, appears to
be overly optimistic. Using a more conservative estimate
for hazard ratio change to 0.7 (30% reduction in hazard),
conducting a 21-day study and applying our feasibility/
pilot data to our sample size estimation, together indi-
cate a sample size requirement of 724 with 362 in each
arm and 253 events (incident delirium) for the main
study. This sample size requirement, 304 (72%) greater
than the pre-study projection, highlights yet again the
need for multisite collaboration in the main study,
assuming that survival analysis with time-to-event
(incident delirium diagnosis) is used as the primary
outcome. An alternative approach, as adopted in a
current Australian multi-site RCT designed to exam-
ine the role of melatonin in preventing delirium in PC
settings, and in which members of our study team
(MA, SB, PL, DC) are also involved, is to use delirium-
free days as the primary outcome, while adjusting for
length of inpatient stay. Using this as primary outcome
has the advantage of having a smaller sample size
requirement.
The severity of incident delirium (based on Nu-DESC,
MDAS and CGR) and the severity of insomnia (based on
ISI scores) are two secondary outcomes in the main
study. The completion rates of Nu-DESC scores and rat-
ings of CGR were acceptable and their respective scores
were similar in the two study treatment groups, with the
caveat that this study was not powered to detect a group
difference. The proportions of missing MDAS scores
(43%) and ISI scores for D14 (53%) and D28 (72%) pre-
cluded meaningful analyses in relation to both of these
measures. The missing MDAS scores due to lack of
CRN/CRA availability at weekends could be corrected
by funding more extensive CRN/CRA coverage, whereas
extreme patient fatigue and the consequent burden of
conducting the MDAS assessment in such patients is
less easily amenable to modification, albeit that based on
available scores, pro-rating of scores for burdensome in-
dividual MDAS items has been reported [61]. Given that
delirium severity measurement is a secondary rather
than primary objective, consideration could be given to
omitting the MDAS assessments in the main study for
valid reasons: delirium severity is already captured by
the CGR and the Nu-DESC, and our having previously
reported moderate correlation between MDAS (as gold
standard) and Nu-DESC scores in a Nu-DESC validation
study [62]. The missing ISI scores due to patients’ dis-
charge prior to reaching 28 days of the study could be
addressed in the main study by omitting D14 and D21
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ratings, and instead either conduct ratings on D7 of the
study or rely solely on ESAS-r ratings for sleep.
Acceptability of study procedures and assessments
Acceptability of study procedures were reflected by a
single protocol violation and a moderate degree of
protocol deviations, mostly in relation to assessment tool
ratings. Although CRN/CRA field notes indicated good
acceptability of core study procedures from a patient
and healthcare staff perspective, there were some
remarkable instances of missing data, particularly in
relation to the MDAS and ISI ratings, both amenable to
solutions as previously discussed.
Secondary objectives of the feasibility study
The study facilitated the implementation of delirium
assessment and management guidelines, which will be
reported separately. Safety evaluation of the study medi-
cation revealed no serious medication related adverse
events. Although the discontinuation of melatonin in
two participants with drowsiness was attributed as most
likely due to other observed illness complications, we
cannot exclude the potential for some contribution of
melatonin to the drowsiness. The feasibility examination
of collecting delirium risk factor data was highly inform-
ative towards planning a main study.
Although few studies have reported risk models for
delirium in palliative care settings or palliative care eli-
gible populations, [63] the baseline delirium risk factors
identified in this study, poorer functional and cognitive
performance and a higher frequency of baseline deficits
in attentional capacity, are consistent with existing data
from oncology settings [64, 65]. Data regarding CRP and
ADS were not obtained as pre-planned. Although in-
creasing anticholinergic drug burden in palliative care
patients has been reported in association with delirium
in a retrospective case-control study, [66] and cognitive
impairment towards death in a secondary analysis of
longitudinal data from an RCT, [67] there are remark-
ably conflicting data in many elderly and critical care
studies regarding the role of anticholinergic drug bur-
den, serum anticholinergic activity and scales to assess
anticholinergic drug burden in relation to delirium risk
[68–71]. In view of such uncertainty, anticholinergic
drug burden evaluation could be omitted in the main
study. In the case of low availability of CRP data, the
goals of care on admission, designated as comfort only
in 13 (22%) patients may have influenced physicians’ de-
cision not to request CRP levels.
Moreover, the study demonstrated a temporal trend
towards an increasing focus on comfort only: of the 21
participants who developed incident delirium, 12 (57%)
had their goals of care designated as comfort only at that
time. This trend is consistent with increasing awareness
of disease progression and is in accordance with the fun-
damental principles of palliative care. However, the
evaluation of predisposing and precipitating risk factors
for delirium in a research study is compromised in this
context, as confounding may occur due to the goals of
care designation and its change over time. One ethically
acceptable solution is to restrict investigation and evalu-
ation of delirium risk factors to those whose goals of
care are designated as “medical”, “medical and transfer”
or “full resuscitation”.
In a larger RCT on delirium prevention, it is advisable
to have good baseline data on covariates, pending pa-
tient consent for investigation, and adjust for them in
the study analyses. More comprehensive epidemio-
logical evaluation of delirium risk factors warrants a
prospective cohort study to obtain robust data. The
number of risk factors evaluated in the feasibility study
was very large; it is possible that examination of exist-
ing databases may allow the selection of a smaller num-
ber of factors for either the planned RCT on prevention
or a more comprehensive prospective cohort study of
delirium risk factors [63].
Strengths and limitations
This study met all of its clearly defined objectives and
provided very useful feasibility and pilot data to inform
the planning and conduct of a larger double blind RCT,
albeit with some important modifications. The sample
size of 60 was consistent with literature recommenda-
tions of at least 9% of the projected sample size of the
main RCT and adequate to meet the objectives of the
study. The study provided useful preliminary informa-
tion to be cautiously interpreted in accordance with lit-
erature recommendations [72]. The feasibility study’s
randomization process resulted in two study groups that
were well balanced and comparable. The study had some
important limitations apart from the limited ability to
evaluate efficacy. First, although we did not survey pa-
tients regarding the effectiveness of blinding process,
there were no signs of any deficits in this regard. Second,
although the study identified substantive areas of miss-
ing data, particularly in relation to follow-up assessment
tool scores and the recording of risk factors, this has en-
abled more appropriate planning towards a larger RCT.
Overall, the distribution of missing baseline neurocogni-
tive and other data across the main study groups was
similar and likely of a random nature. Third, the poten-
tial for underdiagnosis of delirium among study partici-
pants at baseline cannot be excluded and could be
reduced by gaining information from the addition of a
more elaborate assessment tool such as the Delirium
Rating-Revised-98 (DRS-98) [73] or MDAS at the base-
line assessment.
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Conclusion
In meeting its pre-defined objectives, this study ad-
equately assessed the feasibility of conducting a double
blind RCT to examine the role of exogenous melatonin
to prevent delirium in patients with advanced cancer
who were admitted to an inpatient palliative care unit. A
larger double-blind RCT is feasible, but subject accrual
and withdrawal rates signal a need for adjustment in
sample size and multisite collaboration. Although not
powered for efficacy evaluation, the trend for shorter
time to incident delirium in the melatonin group bodes
for careful monitoring in a larger trial. The ethically ac-
ceptable evaluation of risk factors for delirium in re-
search studies warrants careful consideration in light of
the agreed goals of care and their temporal shift towards
more comfort focussed care.
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